[Biomechanical footwear for knee osteoarthritis](https://www.doi.org/10.1001/jama.2020.3565){#interrefs10} {#cesec10}
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Individually calibrated biomechanical footwear therapy could improve pain in people with knee osteoarthritis, according to the single-centre BIOTOK randomised trial by Stephan Reichenbach and colleagues. 220 patients with symptomatic, radiologically confirmed knee osteoarthritis were randomly assigned (1:1) to wear biomechanical footwear with individually adjustable external convex pods attached to the outsole (n=111) or control footwear (n=109) with non-adjustable outsole pods that did not create a convex walking surface. Knee pain at 24 weeks, assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore (the primary outcome; scale of 0 \[no symptoms\] to 10 \[extreme symptoms\]), improved from 4·3 to 1·3 in the biomechanical footwear group and from 4·0 to 2·6 in the control group (between-group difference −1·3 \[95% CI −1·8 to −0·9\]; p\<0·001). Three (2·7%) serious adverse events were reported in the biomechanical footwear group versus nine (8·3%) in the control group; none of these events was deemed related to study treatments.

[Long-term rituximab for ANCA-associated vasculitis](https://www.doi.org/10.7326/M19-3827){#interrefs20} {#cesec20}
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Extended therapy with biannual rituximab infusions was associated with a reduced incidence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in patients with granulomatosis with polyangiitis or microscopic polyangiitis, in a multicentre, randomised controlled trial. Pierre Charles and colleagues randomly assigned 97 patients (1:1) to receive rituximab (n=50) or placebo (n=47) infusions every 6 months for 18 months. Relapse-free survival at 28 months (the primary outcome) was achieved by 96% (95% CI 91--100) of patients in the rituximab group versus 74% (63--88) in the placebo group (hazard ratio 7·5 \[95% CI 1·67--33·7\]; p=0·008). 12 (24%) patients in the rituximab group and 14 (30%) in the placebo group had at least one serious adverse event; nine infectious serious adverse events occurred in six (12%) patients on rituximab versus six such events in four (9%) patients on placebo.

[TNF inhibitors and inflammatory CNS events](https://www.doi.org/10.1001/jamaneurol.2020.1162){#interrefs30} {#cesec30}
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To assess the association between exposure to TNF inhibitors and inflammatory demyelinating and non-demyelinating CNS events, Amy Kunchok and colleagues did a nested case-control study using the medical records of patients with autoimmune diseases treated at three Mayo Clinic locations in the USA. 212 patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis or psoriatic arthritis, Crohn\'s disease, or ulcerative colitis were included: these were divided into 106 patients with inflammatory CNS events and 106 control participants matched for age, autoimmune disease, and sex. 64 (60%) patients with inflammatory CNS events had received a TNF inhibitor versus 42 (40%) in the control group. In a conditional logistic regression model adjusted for disease duration, exposure to TNF inhibitors was associated with an increased risk of inflammatory CNS events (adjusted odds ratio \[OR\] 3·01 \[95% CI 1·55--5·82\]; p=0·001). This association was predominantly seen in patients with rheumatoid arthritis (adjusted OR 4·82 \[1·62--14·36\]; p=0·005).

[Rheumatic disease and hospital admission for COVID-19](https://www.doi.org/10.1136/annrheumdis-2020-217871){#interrefs40} {#cesec40}
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Using data from the COVID-19 Global Rheumatology Alliance registry, Milena Gianfrancesco and colleagues report on 600 cases from across 40 countries and identify factors associated with hospital admission for COVID-19 in people with rheumatic disease. 227 (46%) patients were admitted to hospital and 55 (9%) died. In multivariable-adjusted models, patients receiving a prednisone dose of 10 mg per day or higher had an increased likelihood of hospital admission for COVID-19 (OR 2·05 \[95% CI 1·06--3·96\]), and patients on TNF inhibitors had a reduced likelihood of hospital admission for COVID-19 (0·40 \[0·19--0·81\]). However, use of conventional disease-modifying antirheumatic drugs (DMARDs; 1·23 \[0·70--2·17\] alone and 0·74 \[0·37--1·46\] in combination with biological drugs or Janus kinase inhibitors), non-steroidal anti-inflammatory drugs (0·64 \[0·39--1·06\]), or antimalarials (0·94 \[0·57--1·57\]) was not associated with hospital admission for COVID-19.

[Secukinumab for Behçet\'s syndrome](https://www.doi.org/10.1136/annrheumdis-2020-217108){#interrefs50} {#cesec50}
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Long-term treatment with secukinumab is safe and effective for patients with mucosal or articular Behçet\'s syndrome that is refractory to previous treatments, according to a multicentre, retrospective study reported by Filippo Fagni and colleagues. Of 15 patients with a mucosal or articular phenotype of Behçet\'s syndrome that was refractory to treatment with colchicine, DMARDs, and at least one TNF inhibitor, six with polyarticular involvement were treated with 300 mg per month secukinumab and all other patients started treatment on 150 mg per month secukinumab. A complete or partial response was achieved by ten (67%) of 15 patients at 3 months, 13 (87%) of 15 patients at 6 months, ten (77%) of 13 patients at 12 months, nine (90%) of ten patients at 18 months, and eight (100%) of eight patients at 24 months. All patients who started on a dose of 300 mg per month achieved a complete response by 6 months; seven (47%) patients achieved a response only after increasing the dose to 300 mg per month.
